Results 161 to 170 of about 61,568 (292)

An Unusual Case of Myositis Ossificans [PDF]

open access: bronze, 1967
C W Venables, Harold Ellis
openalex   +1 more source

Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies

open access: yesThe Journal of Pathology, Volume 266, Issue 4-5, Page 369-389, August 2025.
Abstract Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms,
Larissa E Vlaming‐van Eijk   +5 more
wiley   +1 more source

A network of core and subtype-specific gene expression programs in myositis

open access: yesActa Neuropathologica, 2021
David R. Amici   +4 more
semanticscholar   +1 more source

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review

open access: yesJournal of Diabetes, Volume 17, Issue 8, August 2025.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated substantial weight loss effects among patients with diabetes and obesity. However, given the rapid weight loss induced, there is concern about the total change in body composition, including lean body mass (LBM).
Jimmy Wen   +8 more
wiley   +1 more source

The Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 137, Issue 2, August 2025.
ABSTRACT A drug preferred for its antimalarial effect called hydroxychloroquine (HCQ) has long been used to manage and avoid malaria. Nevertheless, its exact mode of action is still unknown. HCQ works through a variety of strategies to influence distinct molecular and cellular pathways.
Ilker Ates   +4 more
wiley   +1 more source

Efgartigimod as a Fast‐Acting Add‐On Therapy in Antibody–Mediated Autoimmune Encephalitis

open access: yesEuropean Journal of Neurology, Volume 32, Issue 8, August 2025.
ABSTRACT Background Autoimmune encephalitis (AE) is a severe neurological disorder that requires effective and safe treatment options. This study aimed to compare the efficacy and safety of intravenous methylprednisolone (IVMP) plus efgartigimod (IPE) versus IVMP alone or IVMP plus immunoglobulin (IPI) as initial treatments for antibody‐mediated AE ...
Zhuajin Bi   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy